<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04372290</url>
  </required_header>
  <id_info>
    <org_study_id>CSD190401</org_study_id>
    <nct_id>NCT04372290</nct_id>
  </id_info>
  <brief_title>CSD190401: A Study to Assess Elements of Abuse Liability for Nicotine-containing Pouch Tobacco Products</brief_title>
  <official_title>CSD190401: An In-Clinic Confinement Study to Assess Elements of Abuse Liability for Nicotine-containing Pouch Tobacco Products</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RAI Services Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RAI Services Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single site, open-label, randomized, cross-over study designed to evaluate elements&#xD;
      of abuse liability (AL) including subjective effects and physiological measures&#xD;
      (pharmacodynamics [PD]) and plasma nicotine uptake (pharmacokinetics [PK]) during and&#xD;
      following ad libitum use of the study investigational products (IPs) by generally healthy&#xD;
      subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cigarette smokers (SMK) and smokers who also use smokeless tobacco (SST) [e.g., snus, moist&#xD;
      snuff] will be recruited into the study. An attempt will be made to have approximately one&#xD;
      third of the study population made up of SST.&#xD;
&#xD;
      Potential subjects may complete a pre-Screening telephone interview and will complete a&#xD;
      Screening Visit to assess their eligibility within 45 days prior to check-in and&#xD;
      enrollment/randomization.&#xD;
&#xD;
      Starting on Day -1, eligible subjects will begin confinement at the clinical site for 6 days.&#xD;
      Subjects will be randomized to evaluate one investigational product (IP) in each of five&#xD;
      separate Test Sessions, such that each subject will evaluate five IPs, including three&#xD;
      strengths of the nicotine pouches, and both a high- and a low-AL comparator.&#xD;
&#xD;
      Each Test Session will last for approximately 4 hours during and following IP use and will&#xD;
      include collection of both PD measures (subjective and physiological) and PK measures.&#xD;
&#xD;
      On Day -1, subjects will participate in an IP acclimation period where they will be&#xD;
      instructed on how to use the nicotine pouch IP and the nicotine gum (low-AL comparator IP).&#xD;
      At the end of the acclimation period, subjects will have access to their usual brand (UB)&#xD;
      cigarettes for ad libitum use until the 12-hour tobacco abstinence begins prior to the Day 1&#xD;
      Test Session.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 6, 2020</start_date>
  <completion_date type="Actual">June 4, 2020</completion_date>
  <primary_completion_date type="Actual">June 4, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUECPL 5-240</measure>
    <time_frame>5 minutes to 240 minutes</time_frame>
    <description>area-under-the-effects curve (AUEC) for PL numeric rating scale (NRS) score-versus-time curve from 5 minutes to 240 minutes after the start of IP use.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Emax PL</measure>
    <time_frame>240 minutes</time_frame>
    <description>maximum product liking (PL) numeric rating scale (NRS) score after the start of IP use.</description>
  </primary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Smoking</condition>
  <condition>Smoking Behaviors</condition>
  <condition>Tobacco Use</condition>
  <condition>Tobacco Smoking</condition>
  <arm_group>
    <arm_group_label>Product usage order ABECD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 5 products sequentially (ABECD) during an evaluation period, followed by a 6 hour Test Session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order BCADE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 5 products sequentially (BCADE) during an evaluation period, followed by a 6 hour Test Session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order CDBEA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 5 products sequentially (CDBEA) during an evaluation period, followed by a 6 hour Test Session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order DECAB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 5 products sequentially (DECAB) during an evaluation period, followed by a 6 hour Test Session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order EADBC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 5 products sequentially (EADBC) during an evaluation period, followed by a 6 hour Test Session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order DCEBA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 5 products sequentially (DCEBA) during an evaluation period, followed by a 6 hour Test Session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order EDACB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 5 products sequentially (EDACB) during an evaluation period, followed by a 6 hour Test Session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order AEBDC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 5 products sequentially (AEBDC) during an evaluation period, followed by a 6 hour Test Session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order BACED</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 5 products sequentially (BACED) during an evaluation period, followed by a 6 hour Test Session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order CBDAE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 5 products sequentially (CBDAE) during an evaluation period, followed by a 6 hour Test Session.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Product A</intervention_name>
    <description>Usual brand (UB) filtered, combustible cigarette</description>
    <arm_group_label>Product usage order ABECD</arm_group_label>
    <arm_group_label>Product usage order AEBDC</arm_group_label>
    <arm_group_label>Product usage order BACED</arm_group_label>
    <arm_group_label>Product usage order BCADE</arm_group_label>
    <arm_group_label>Product usage order CBDAE</arm_group_label>
    <arm_group_label>Product usage order CDBEA</arm_group_label>
    <arm_group_label>Product usage order DCEBA</arm_group_label>
    <arm_group_label>Product usage order DECAB</arm_group_label>
    <arm_group_label>Product usage order EADBC</arm_group_label>
    <arm_group_label>Product usage order EDACB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Product B</intervention_name>
    <description>Nicorette® White Ice Mint 2 mg nicotine gum</description>
    <arm_group_label>Product usage order ABECD</arm_group_label>
    <arm_group_label>Product usage order AEBDC</arm_group_label>
    <arm_group_label>Product usage order BACED</arm_group_label>
    <arm_group_label>Product usage order BCADE</arm_group_label>
    <arm_group_label>Product usage order CBDAE</arm_group_label>
    <arm_group_label>Product usage order CDBEA</arm_group_label>
    <arm_group_label>Product usage order DCEBA</arm_group_label>
    <arm_group_label>Product usage order DECAB</arm_group_label>
    <arm_group_label>Product usage order EADBC</arm_group_label>
    <arm_group_label>Product usage order EDACB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Product C</intervention_name>
    <description>CSD1904-01, a nicotine pouch, 2 mg nicotine</description>
    <arm_group_label>Product usage order ABECD</arm_group_label>
    <arm_group_label>Product usage order AEBDC</arm_group_label>
    <arm_group_label>Product usage order BACED</arm_group_label>
    <arm_group_label>Product usage order BCADE</arm_group_label>
    <arm_group_label>Product usage order CBDAE</arm_group_label>
    <arm_group_label>Product usage order CDBEA</arm_group_label>
    <arm_group_label>Product usage order DCEBA</arm_group_label>
    <arm_group_label>Product usage order DECAB</arm_group_label>
    <arm_group_label>Product usage order EADBC</arm_group_label>
    <arm_group_label>Product usage order EDACB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Product D</intervention_name>
    <description>CSD1904-02, a nicotine pouch, 4 mg nicotine</description>
    <arm_group_label>Product usage order ABECD</arm_group_label>
    <arm_group_label>Product usage order AEBDC</arm_group_label>
    <arm_group_label>Product usage order BACED</arm_group_label>
    <arm_group_label>Product usage order BCADE</arm_group_label>
    <arm_group_label>Product usage order CBDAE</arm_group_label>
    <arm_group_label>Product usage order CDBEA</arm_group_label>
    <arm_group_label>Product usage order DCEBA</arm_group_label>
    <arm_group_label>Product usage order DECAB</arm_group_label>
    <arm_group_label>Product usage order EADBC</arm_group_label>
    <arm_group_label>Product usage order EDACB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Product E</intervention_name>
    <description>CSD1904-02, a nicotine pouch, 8 mg nicotine (simultaneous use of two 4 mg nicotine pouches)</description>
    <arm_group_label>Product usage order ABECD</arm_group_label>
    <arm_group_label>Product usage order AEBDC</arm_group_label>
    <arm_group_label>Product usage order BACED</arm_group_label>
    <arm_group_label>Product usage order BCADE</arm_group_label>
    <arm_group_label>Product usage order CBDAE</arm_group_label>
    <arm_group_label>Product usage order CDBEA</arm_group_label>
    <arm_group_label>Product usage order DCEBA</arm_group_label>
    <arm_group_label>Product usage order DECAB</arm_group_label>
    <arm_group_label>Product usage order EADBC</arm_group_label>
    <arm_group_label>Product usage order EDACB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able to read, understand, and willing to sign an informed consent form (ICF) and&#xD;
             complete questionnaires written in English.&#xD;
&#xD;
          2. Generally healthy male or female, 21 to 60 years of age, inclusive, at the time of&#xD;
             consent.&#xD;
&#xD;
          3. Expired breath carbon monoxide level is ≥ 10 ppm and ≤ 100 ppm at Screening.&#xD;
&#xD;
          4. Positive urine cotinine test at Screening.&#xD;
&#xD;
          5. Smokes combustible, filtered, non-menthol or menthol cigarettes, 83 mm to 100 mm in&#xD;
             length as primary source of tobacco. Other cigarette sizes may be allowed with sponsor&#xD;
             approval.&#xD;
&#xD;
          6. Smokers who also use smokeless tobacco products may be enrolled.&#xD;
&#xD;
          7. Agrees to smoke same UB cigarette throughout the study period. UB cigarette is defined&#xD;
             as the reported cigarette brand style currently smoked most frequently by the subject.&#xD;
&#xD;
          8. Smokes at least 10 cigarettes per day (on average) and inhales the smoke, for at least&#xD;
             6 months prior to Screening.&#xD;
&#xD;
          9. Response at Screening to Fagerström Test for Nicotine Dependence (FTND) Question 1&#xD;
             (&quot;How soon after you wake up do you smoke your first cigarette?&quot;) is either &quot;Within 5&#xD;
             minutes&quot; or &quot;6-30 minutes.&quot;&#xD;
&#xD;
         10. Willing to use UB cigarette, nicotine pouch products, and Nicorette gum during the&#xD;
             study period.&#xD;
&#xD;
         11. Willing to abstain from tobacco and nicotine use for at least 12 hours prior to each&#xD;
             Test Session.&#xD;
&#xD;
         12. Females must be willing to use a form of contraception acceptable to the Principal&#xD;
             Investigator (PI) from the time of signing informed consent until End-of-Study.&#xD;
&#xD;
         13. Agrees to in-clinic confinement of 6 days (5 nights).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Uses a vapor product (e.g., e-cigarettes, tank systems) more than one day per week,&#xD;
             for the past 6 months prior to screening.&#xD;
&#xD;
          2. Presence of clinically significant uncontrolled cardiovascular, pulmonary, renal,&#xD;
             hepatic, endocrine, gastrointestinal, psychiatric, hematological, neurological&#xD;
             disease, or any other concurrent disease or medical condition that, in the opinion of&#xD;
             the PI, makes the study subject unsuitable to participate in this clinical study.&#xD;
&#xD;
          3. History, presence of, or clinical laboratory test results indicating diabetes.&#xD;
&#xD;
          4. Systolic blood pressure of &gt; 160 mmHg or a diastolic blood pressure of &gt; 95 mmHg,&#xD;
             measured after being seated for five minutes at Screening and at Day -1.&#xD;
&#xD;
          5. Weight of ≤ 110 pounds.&#xD;
&#xD;
          6. Hemoglobin level is &lt; 12.5 g/dL for females or &lt;13.0 g/dL for males at Screening.&#xD;
&#xD;
          7. Scheduled treatment for asthma currently or within the past consecutive 12 months&#xD;
             prior to the Screening Visit. As-needed treatment, such as inhalers, may be included&#xD;
             at the PI's discretion pending approval from the Medical Monitor.&#xD;
&#xD;
          8. Positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen&#xD;
             (HBsAg), or hepatitis C virus (HCV).&#xD;
&#xD;
          9. Any history of cancer, except for primary cancers of skin such as localized basal&#xD;
             cell/squamous cell carcinoma that has been surgically and/or cryogenically removed.&#xD;
&#xD;
         10. Use of any medication or substance that aids in smoking cessation, including but not&#xD;
             limited to any nicotine-replacement therapy (NRT) (e.g., nicotine gum, lozenge,&#xD;
             patch), varenicline (Chantix®), bupropion (Wellbutrin®, Zyban®), or lobelia extract&#xD;
             within (≤) 30 days prior to the signing of informed consent.&#xD;
&#xD;
         11. History or presence of bleeding or clotting disorders.&#xD;
&#xD;
         12. Any use of anticoagulants or aspirin (≥ 325 mg/day).&#xD;
&#xD;
         13. Whole blood donation within 8 weeks (≤ 56 days) prior to the signing of informed&#xD;
             consent.&#xD;
&#xD;
         14. Plasma donation within (≤) 7 days prior to the signing of informed consent.&#xD;
&#xD;
         15. Participation in another clinical trial within (≤) 30 days prior to the signing of&#xD;
             informed consent. The 30-day window for each subject will be derived from the date of&#xD;
             the last study event in the previous study to the time of signing the informed consent&#xD;
             form (ICF) in the current study.&#xD;
&#xD;
         16. Females who have a positive pregnancy test, are pregnant, breastfeeding, or intend to&#xD;
             become pregnant during the course of the study.&#xD;
&#xD;
         17. Individuals ≥ 35 years of age currently using systemic, estrogen-containing&#xD;
             contraception or hormone replacement therapy.&#xD;
&#xD;
         18. A positive urine drug screen without evidence of prescribed corresponding concomitant&#xD;
             medication(s) at Screening or Day -1.&#xD;
&#xD;
         19. Postpones a decision to quit using tobacco- or nicotine-containing products in order&#xD;
             to participate in this study or a previous attempt within (≤) 30 days prior to signing&#xD;
             the ICF.&#xD;
&#xD;
         20. Drinks more than 21 servings of alcoholic beverages per week or has a positive alcohol&#xD;
             screen result at Screening or Day -1.&#xD;
&#xD;
         21. Employed by a tobacco or nicotine company, the study site, or handles tobacco- or&#xD;
             nicotine-containing products as part of their job.&#xD;
&#xD;
         22. Determined by the PI to be inappropriate for this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bobbette Jones, DrPH</last_name>
    <role>Study Director</role>
    <affiliation>RAIS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New Orleans Center for Clinical Research (NOCCR)</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 29, 2020</study_first_submitted>
  <study_first_submitted_qc>April 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2020</study_first_posted>
  <last_update_submitted>September 24, 2020</last_update_submitted>
  <last_update_submitted_qc>September 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

